• Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

CellaVision

135.60 SEK

+0.15 %

1,478 following

CEVI

NASDAQ Stockholm

Medical Equipment & Services

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Compare
+0.15 %
+12.44 %
-8.01 %
-13.74 %
-13.74 %
-25.17 %
-26.38 %
-62.33 %
+769.23 %

CellaVision operates in the medical technology industry and focuses on the development and manufacture of systems for digital blood analysis. The company focuses on digital cell morphology and offers innovations for analyzers, instruments, reagents and software used in hematology laboratories. The company's products are aimed at healthcare institutions and laboratories worldwide. CellaVision was founded in 1994 and is headquartered in Lund, Sweden.

Read more
Market cap
3.23B SEK
Turnover
1.07M SEK
Revenue
758.97M
EBIT %
26.62 %
P/E
21.12
Dividend yield-%
2.03 %
Revenue and EBIT-%
EPS and dividend
Financial calendar
All
Webcasts
Press releases
ShowingAll content types

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
17.7
2026

Interim report Q2'26

29.10
2026

Interim report Q3'26

4.2
2027

Annual report '26

CellaVision, Audiocast, Q2'26
Webcast17.07.2026, 11.00

CellaVision, Audiocast, Q2'26

CellaVision
Regulatory press release05.06.2026, 19.00

The Board of CellaVision AB appoints Steve Ferguson as CEO

CellaVision
Regulatory press release28.04.2026, 16.45

Bulletin from the Annual General Meeting of CellaVision AB (publ)

CellaVision

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
CellaVision, Audiocast, Q1'26
Webcast24.04.2026, 11.00

CellaVision, Audiocast, Q1'26

CellaVision
Regulatory press release24.04.2026, 07.20

Softer quarter due to lower sales in EMEA

CellaVision
Press release21.04.2026, 14.00

Modular Finance IR Consensus: CellaVision – Consensus estimates Q1 2026

CellaVision
Regulatory press release16.04.2026, 11.20

The Nomination Committee’s proposals for the 2026 Annual General Meeting of CellaVision AB

CellaVision
Press release10.04.2026, 08.20

Invitation to Presentation of the CellaVision Report for the First Quarter 2026 on April 24, at 11:00 CEST

CellaVision
Regulatory press release01.04.2026, 08.20

CellaVision publishes its 2025 Annual and Sustainability Report

CellaVision
Regulatory press release25.03.2026, 08.00

NOTICE OF ANNUAL GENERAL MEETING IN CELLAVISION AB (publ)

CellaVision
Press release11.03.2026, 08.20

The new CellaVision® Bone Marrow Aspirate Application launches in EMEA

CellaVision
CellaVision, Audiocast, Q4'25
Webcast05.02.2026, 11.00

CellaVision, Audiocast, Q4'25

CellaVision
Regulatory press release05.02.2026, 07.20

Solid Quarter driven by Strong Performance in Americas

CellaVision
Press release02.02.2026, 15.00

Modular Finance IR Consensus: CellaVision – Consensus estimates Q4 2025

CellaVision
Press release22.01.2026, 08.20

Invitation to Presentation of the CellaVision Year-end Report 2025 on February 5, at 11:00 CET

CellaVision
Regulatory press release12.12.2025, 15.00

CellaVision appoints Monica Jönsson as new CFO

CellaVision
Regulatory press release08.12.2025, 07.20

CellaVision receives CE marking according to IVDR Class C for CellaVision® Bone Marrow Aspirate Application

CellaVision
CellaVision, Audiocast, Q3'25
Webcast06.11.2025, 11.00

CellaVision, Audiocast, Q3'25

CellaVision
Regulatory press release06.11.2025, 07.20

Softer Quarter with Mixed Regional Performance

CellaVision
Press release03.11.2025, 15.00

Modular Finance IR Consensus: CellaVision – Consensus estimates Q3 2025

CellaVision